Eli Lilly shares jumped 14% on Thursday after the pharmaceutical giant posted a strong second-quarter earnings report, driven by the popularity of its GLP-1 weight-loss drugs.

The company’s revenue reached $11.3 billion, surpassing analysts’ estimates of $9.98 billion. Adjusted earnings per share (EPS) came in at $3.92, significantly higher than the projected $2.76.

JPMorgan, which rated Eli Lilly as “Overweight” with a $1,000 price target, highlighted the potential for further growth in the company’s stock due to increased production capacity and the upcoming launch of new drugs, such as Orfoglipron, a GLP-1 pill currently in clinical trials.